Advertisement
Patients with peanut allergy who received oral immunotherapy

ACAAI: Oral Immunotherapy Is Protective in Peanut Allergy

0
More patients receiving AR101 able to ingest ≥600 mg peanut protein without dose-limiting symptoms
The prevalence of food allergy is 7.6 percent among children in the United States

Prevalence of Food Allergy 7.6 Percent in U.S. Children

0
Most prevalent allergens are peanut, milk, shellfish, and tree nut
Almost 2 percent of children in the United States have a milk allergy

ACAAI: Almost 2 Percent of Children Have Milk Allergy

0
Among children with food allergy, 53 percent of infants have milk allergy vs. 15 percent of teens
For children hospitalized with asthma exacerbations

ACAAI: Hospital Stay, Caregiver Knowledge of Asthma Linked

0
Children of caregivers with poor asthma knowledge more likely to have prolonged hospital stay
In the first six months of 2018

CDC: 8.8 Percent Uninsured in U.S. in First Half of 2018

0
12.5 percent of adults aged 18-64 years and 4.4 percent of children aged 0-17 years uninsured
In a simulation of children with peanut allergy

Epinephrine Personal Autoinjectors Cost-Effective at $24

0
Based on 10-fold fatality risk difference, value-based price for personal epinephrine $24
Data from patient- and family-reported error narratives indicate that problems related to patient-physician interactions are major contributors to diagnostic errors

Patient Experiences Shed Light on Diagnostic Errors

0
Problems related to patient-physician interactions contribute to diagnostic errors
Rising drug spending in the United States is being fueled by expensive name-brand prescription medicines

Name-Brand Medications Driving Spike in U.S. Drug Spending

0
Greatest costs for Humira, Remicade, Enbrel, Novolog, and Neulasta
By collecting data on suicides by medical students

AMA to Collect Data on Suicide Among Doctors-in-Training

0
Administration hopes to identify the systemic factors that contribute to this problem
A new version of an over-the-counter asthma inhaler that was taken off the market in 2011 has been approved by the U.S. Food and Drug Administration.

FDA Approves New Version of OTC Primatene Mist

0
Primatene Mist approved to provide temporary relief for symptoms of mild, intermittent asthma